Earnings summaries and quarterly performance for JOHNSON & JOHNSON.
Executive leadership at JOHNSON & JOHNSON.
Joaquin Duato
Detailed
Chairman and Chief Executive Officer
CEO
JT
Jennifer Taubert
Detailed
Executive Vice President, Worldwide Chairman, Innovative Medicine
JR
John Reed
Detailed
Executive Vice President, Innovative Medicine, R&D
JW
Joseph Wolk
Detailed
Executive Vice President, Chief Financial Officer
KW
Kathryn Wengel
Detailed
Executive Vice President, Chief Technical Operations & Risk Officer
TS
Tim Schmid
Detailed
Executive Vice President, Worldwide Chairman, MedTech
Board of directors at JOHNSON & JOHNSON.
DP
Daniel Pinto
Detailed
Director
DA
Darius Adamczyk
Detailed
Director
EW
Eugene Woods
Detailed
Director
HJ
Hubert Joly
Detailed
Director
JD
Jennifer Doudna
Detailed
Director
JM
John Morikis
Detailed
Director
MH
Marillyn Hewson
Detailed
Lead Independent Director
MM
Mark McClellan
Detailed
Director
MW
Mark Weinberger
Detailed
Director
MB
Mary Beckerle
Detailed
Director
NW
Nadja West
Detailed
Director
PJ
Paula Johnson
Detailed
Director
Research analysts who have asked questions during JOHNSON & JOHNSON earnings calls.
CS
Christopher Schott
JPMorgan Chase & Co.
6 questions for JNJ
Also covers: ABBV, AMGN, AMRX +15 more
Terence Flynn
Morgan Stanley
6 questions for JNJ
Also covers: ABBV, AMGN, ARVN +17 more
LB
Larry Biegelsen
Wells Fargo & Company
5 questions for JNJ
Also covers: ABT, ALC, AXNX +24 more
Vamil Divan
Guggenheim Securities
5 questions for JNJ
Also covers: ABBV, ABSI, ANIP +7 more
AH
Asad Haider
Goldman Sachs
4 questions for JNJ
Also covers: ABBV, BMY, BNTX +4 more
SS
Shagun Singh Chadha
RBC Capital Markets
4 questions for JNJ
Also covers: AXNX, DXCM, GMED +11 more
DA
Danielle Antalffy
UBS Group AG
3 questions for JNJ
Also covers: ABT, ATRC, BAX +15 more
Jayson Bedford
Raymond James
3 questions for JNJ
Also covers: AXGN, DXCM, IART +7 more
AH
Alexandria Hammond
Wolfe Research
2 questions for JNJ
Also covers: ABBV, AMGN, BMRN +6 more
AH
Alex Hammond
Sidoti & Company, LLC
2 questions for JNJ
Also covers: BMRN, CBUS, LLY +1 more
DA
Danielle Antalffy
UBS
2 questions for JNJ
Also covers: ATRC, BSX, DXCM
Matt Miksic
Barclays Investment Bank
2 questions for JNJ
Also covers: ABT, ATEC, BAX +14 more
TA
Timothy Anderson
BofA Securities
2 questions for JNJ
Also covers: ABBV, AMGN, AZN +10 more
DC
David Chen
Goldman Sachs Group, Inc.
1 question for JNJ
DR
David Reisinger
Lyriq
1 question for JNJ
DR
David Risinger
Leerink Partners
1 question for JNJ
Also covers: ABBV, AMGN, BMY +9 more
Joanne Wuensch
Citigroup Inc.
1 question for JNJ
Also covers: ABT, BAX, BDX +18 more
JJ
Joshua Jennings
TD Cowen
1 question for JNJ
Also covers: ABT, ALUR, ATEC +20 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for JNJ
Also covers: ABT, ALC, BAX +16 more
LC
Louise Chen
Cantor Fitzgerald
1 question for JNJ
Also covers: ARDX, CNTB, IMAB +14 more
Matthew Miksic
Barclays PLC
1 question for JNJ
Also covers: ABT, ATEC, BAX +15 more
Recent press releases and 8-K filings for JNJ.
Johnson & Johnson strikes drug-price deal with Trump administration
JNJ
New Projects/Investments
- Johnson & Johnson agreed to join the TrumpRx direct-to-patient platform, promising to lower U.S. drug prices and align some Medicaid pricing with rates in other developed countries in exchange for tariff exemptions; key terms remain confidential.
- Selected medicines will be offered at significant discounts, but the size of price cuts and duration of tariff relief have not been disclosed.
- The company reaffirmed its $55 billion U.S. investment plan, including new manufacturing facilities in Pennsylvania and North Carolina.
- Shares slipped about 0.5% on the announcement (closing at $205.75), as investors await more detail at the J.P. Morgan Healthcare Conference on Jan. 12 and Q4 results on Jan. 21.
3 hours ago
Johnson & Johnson reaches U.S. drug access agreement and advances U.S. investments
JNJ
New Projects/Investments
- Johnson & Johnson entered a voluntary agreement with the Trump Administration to improve access to medicines and lower patient costs, including an exemption from U.S. tariffs on its pharmaceuticals.
- The company will participate in TrumpRx.gov and align its U.S. drug pricing and Medicaid program prices with those in other developed countries.
- J&J is progressing on its $55 billion U.S. investment, announcing two new manufacturing facilities in Pennsylvania and North Carolina and advancing a $2 billion biologics site in Wilson, NC.
22 hours ago
Johnson & Johnson reports positive Phase 2b nipocalimab data in SLE
JNJ
New Projects/Investments
- Positive topline results from the Phase 2b JASMINE trial showed nipocalimab met the primary endpoint (SRI-4 at Week 24) with statistical significance versus placebo.
- Achieved key secondary and exploratory endpoints, including signals of steroid-sparing potential, with no new safety signals observed.
- Nipocalimab is the first investigational FcRn blocker to demonstrate efficacy in active SLE in a 52-week, 228-patient, multicenter study.
- Based on these results, the company will initiate a Phase 3 program for nipocalimab in SLE.
3 days ago
Johnson & Johnson completes acquisition of Halda Therapeutics
JNJ
M&A
- Johnson & Johnson agreed to acquire clinical-stage biotech Halda Therapeutics OpCo, Inc. for $3.05 billion in cash.
- Halda’s proprietary RIPTAC™ platform targets the development of oral, targeted therapies for multiple solid tumors, including prostate cancer.
- This strategic acquisition underscores J&J’s commitment to advancing next-generation oral cancer treatments.
Dec 29, 2025, 3:27 PM
Johnson & Johnson completes $3.05B Halda acquisition
JNJ
M&A
New Projects/Investments
- Johnson & Johnson completed its $3.05 billion acquisition of Halda Therapeutics on Dec. 29, 2025, gaining the company’s proprietary RIPTAC platform and the once-daily oral prostate cancer candidate HLD-10915.
- The deal adds early RIPTAC-based programs for breast, lung and other solid tumors, positioning J&J to expand targeted therapies beyond oncology.
- The transaction will dilute adjusted EPS by ~$0.20 per share in late 2025 and 2026 and is being accounted for as a business combination.
- This move follows J&J’s April acquisition of Intra-Cellular Therapies for $14.6 billion and the recent FDA expanded-use approval for Caplyta, the first approved drug from that deal.
- Johnson & Johnson’s stock rose 28–44% in 2025 as investors reacted to easing regulation and faster earnings growth.
Dec 29, 2025, 1:07 PM
Johnson & Johnson completes acquisition of Halda Therapeutics
JNJ
M&A
New Projects/Investments
- Johnson & Johnson closed its acquisition of Halda Therapeutics for $3.05 billion in cash, adding a proprietary RIPTAC™ platform to its oncology portfolio.
- The deal brings in HLD-0915, a once-daily oral therapy targeting prostate cancer, plus earlier-stage candidates for breast, lung and other solid tumors.
- The acquisition will be accounted for as a business combination, with an expected $0.20 per share dilution to adjusted EPS, split equally between Q4 2025 and 2026.
- Full-year 2026 guidance commentary will be provided during J&J’s Q4 earnings call on January 21, 2026.
Dec 29, 2025, 1:00 PM
Johnson & Johnson halts mid-stage eczema trial
JNJ
- Johnson & Johnson terminated its Phase 2b DUPLEX-AD study of JNJ-15939 for moderate-to-severe atopic dermatitis after a planned interim analysis failed to meet efficacy targets, though the drug was well tolerated.
- The company remains committed to advancing other pipeline candidates, including NM26, PX128, PX130 and the oral STAT6 inhibitor KP-723.
- Shares dipped amid mixed investor reactions against a backdrop of a $1.5 billion talc verdict, thousands of pending cases and recent insider selling (six open-market trades in six months).
- Financially, J&J reported $24 billion in Q3 2025 revenues (up ~6.8% YoY), a 1.07 current ratio and 0.58 debt/equity, but valuation metrics near historical highs (market cap ~$500.6 billion, P/E ~20.06) with a 3.7% decline in operating cash flow.
Dec 26, 2025, 1:17 PM
Johnson & Johnson ordered to pay $1.56B in talc lawsuit
JNJ
Legal Proceedings
- A Baltimore jury awarded $1.56 billion in damages (including $59.84 million compensatory, $1 billion punitive against J&J and $500 million against Pecos River Talc) — the largest single-plaintiff verdict in the talc litigation.
- J&J plans to immediately appeal, calling the verdict “egregious” and continues to deny its talc products contain asbestos.
- The company faces over 67,000 pending talc-related lawsuits, and prior bankruptcy-based settlement plans worth billions were rejected by courts.
- Despite the ruling, J&J’s financial position remains strong with a $499.5 billion market cap, 1.07 current ratio, 0.58 debt-to-equity ratio, Altman Z-Score of 3.68 and Beneish M-Score of −2.54.
Dec 23, 2025, 2:33 PM
Johnson & Johnson receives FDA approval for TRUFILL n-BCA in chronic subdural hematoma
JNJ
Product Launch
- FDA approved expanded indication for the TRUFILL n-BCA Liquid Embolic System for embolization of the middle meningeal artery in adjunctive treatment of symptomatic subacute and chronic subdural hematoma, leveraging over 25 years of neurovascular use.
- The MEMBRANE randomized trial showed TRUFILL n-BCA was superior in effectiveness and safe versus standard of care, with a treatment effect of 0.475 (95% CI 0.239–0.944) in the surgical cohort.
- Chronic subdural hematoma carries a 10–20% recurrence rate with traditional surgery, and MMA embolization offers a minimally invasive alternative to address residual bleeding.
Dec 18, 2025, 1:00 PM
Johnson & Johnson receives FDA approval for RYBREVANT FASPRO subcutaneous NSCLC therapy
JNJ
Product Launch
- FDA approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the first subcutaneous therapy for EGFR-mutated non-small cell lung cancer, covering all indications of RYBREVANT®.
- Administration time reduced from hours to approximately 5 minutes, with a fivefold decrease in administration-related reactions (13% vs 66%) and lower venous thromboembolism incidence (11% vs 18%) compared to IV delivery.
- In the Phase 3 PALOMA-3 trial, the subcutaneous regimen met co-primary pharmacokinetic endpoints and showed 65% vs 51% 12-month overall survival for SC vs IV administration.
- Builds on Phase 3 MARIPOSA data where RYBREVANT plus LAZCLUZE® achieved a 25% reduction in death risk vs osimertinib (HR 0.75; 95% CI 0.61–0.92; P=0.0048) with median OS projected to exceed 4 years vs 36.7 months for osimertinib.
Dec 17, 2025, 11:49 PM
Fintool News
In-depth analysis and coverage of JOHNSON & JOHNSON.
Quarterly earnings call transcripts for JOHNSON & JOHNSON.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more